CN2576179Y - Novel blood-vessel embolism material - Google Patents
Novel blood-vessel embolism material Download PDFInfo
- Publication number
- CN2576179Y CN2576179Y CN 02248907 CN02248907U CN2576179Y CN 2576179 Y CN2576179 Y CN 2576179Y CN 02248907 CN02248907 CN 02248907 CN 02248907 U CN02248907 U CN 02248907U CN 2576179 Y CN2576179 Y CN 2576179Y
- Authority
- CN
- China
- Prior art keywords
- embolism materials
- analgesic
- novel vascular
- spring
- microgranule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model relates to a novel blood vessel embolism material which comprises an anodyne and an embolism material, wherein the anodyne is mixed in the embolism material or is attached on the embolism material so as to form a granular structure, or a nubbly structure, or a linear structure, or a spring-shaped structure. The problem of the target ischemic pain of patients after blood vessel embolism operations can be effectively prevented through the slow release of the anodyne; therefore, the pain of the patients is relieved and the utility model is popular with the patients.
Description
This utility model relates to a kind of intervention vascular suppository material.
In the prior art, multiple intervention vascular suppository material has been arranged, mainly contain polyvinyl alcohol (Polyvinyl Alcohol, PVA), gelfoam, surgical thread, stainless steel spring circle, platinum microcoils, taking off property sacculus, alpha-cyanoacrylate (cyanoacrylates), dewatered ethanol, iodized oil, sodium morrhuate etc.Avascular pain often appears in target in clinical use, and patient's postoperative need be injected analgesic or oral analgesic.
The purpose of this utility model is that a kind of novel vascular embolism materials will be provided, and it solves blood vessel embolism postoperative patient target avascular pain problem effectively, has alleviated patient's misery.
The purpose of this utility model is achieved in that
The novel vascular embolism materials, comprise analgesic (1), embolism materials (2), it is characterized in that analgesic (1) be entrained in the embolism materials (2) or analgesic (1) attached on the embolism materials (2), form nutty structure or block structure or linear structure or spring-like structures.
---the analgesic (1) of above-mentioned novel vascular embolism materials can mix with anticarcinogen or other medicines, is entrained in the embolism materials (2) or attached on the embolism materials (2), forms nutty structure or block structure or existing list structure or spring-like structures.
---the embolism materials (2) of above-mentioned novel vascular embolism materials can be the Biodegradable vascular suppository material, as gelfoam, sodium alginate, polyglycolic acid, polylactic acid, Ju diox etc.; Also can be non-Biodegradable vascular suppository material, as metal spring steel ring class: steel rim of spring, Ultimum Ti steel rim of spring, stainless steel spring steel ring, the platinum steel rim of spring of band terylene fiber hair; Macromolecule material particle class: polyvinyl alcohol (Polyvinyl Alcohol, PVA) microgranule, politef microgranule, polyethylene microgranule, polyamine fat microgranule, nylon microgranule etc., perhaps porous material particulate species: POROUS TITANIUM metal particle, porous polyethylene microgranule, porous Teflon microgranule, porous polyethylene alcohol microgranule etc.
---the embolism materials (2) of above-mentioned novel vascular embolism materials can be to develop under the X-ray, also can be that X-ray is nonvisualized.
---the analgesic (1) of above-mentioned novel vascular embolism materials can be that solid-state drug is entrained in the embolism materials (2) or is coated in the embolism materials (2), also can be liquid drug be adsorbed on porous embolism materials (2) micropore (3) in.
---the analgesic (1) of above-mentioned novel vascular embolism materials can be entrained in the embolism materials (2) or attached on the embolism materials (2), discharge gradually by release membranes (4).
This utility model is entrained in analgesic on the Biodegradable vascular suppository material or by slow release method analgesic is coated on the non-biodegradation type vascular suppository material, perhaps analgesic is adsorbed in the micropore of porous non-biodegradation type vascular suppository material, slow release by analgesic, prevented blood vessel embolism postoperative patient target avascular pain problem effectively, alleviated patient's misery, be subjected to the patient and welcome.
Concrete structure of the present utility model and operation principle are provided by following examples:
The graininess of Fig. 1 this utility model is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
The linear of Fig. 2 this utility model is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
The bulk of Fig. 3 this utility model is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
The spring-like of Fig. 3 this utility model is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
The graininess micro-porous adsorption of Fig. 5 this utility model has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
The block micro-porous adsorption of Fig. 6 this utility model has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
The linear micro-porous adsorption of Fig. 7 this utility model has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
The ellipsoid shape micro-porous adsorption of Fig. 8 this utility model has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
The graininess analgesic of Fig. 9 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The block analgesic of Figure 10 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The linear analgesic of Figure 11 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of the linear band release membranes of Figure 12 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of the graininess band release membranes of Figure 13 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of the lump zone release membranes of Figure 14 this utility model is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of Figure 15 this utility model is attached to the structural representation of the helical spring steel ring formula novel vascular embolism materials on the one-level metal coil spring.
The analgesic of Figure 16 this utility model is attached to the structural representation of the turriform steel rim of spring formula novel vascular embolism materials on the one-level metal coil spring.
The analgesic of Figure 17 this utility model is attached to the structural representation of the novel vascular embolism materials on the one-level metal coil spring.
The analgesic of Figure 18 this utility model is attached to the structural representation of the steel rim of spring formula novel vascular embolism materials of the cylinder shape belt terylene fiber hair on the one-level metal coil spring.
The analgesic of Figure 19 this utility model is attached to the structural representation of the steel rim of spring formula novel vascular embolism materials of the turriform band terylene fiber hair on the one-level metal coil spring.
The analgesic of Figure 20 this utility model is attached to the structural representation of the novel vascular embolism materials on the one-level metal coil spring of band terylene fiber hair.
The fundamental diagram of the novel vascular embolism materials of Figure 21 this utility model.
Among the above-mentioned figure: 1 is analgesic, and 2 is embolism materials, and 3 is micropore, and 4 is release membranes, and 5 is the novel vascular embolism materials of this utility model, and 6 is conduit, and 7 is blood vessel.
Select for use morphine as analgesic (1), select for use gelfoam, morphine and gelfoam are mixed and made into microsphere, promptly obtained the Biodegradable novel vascular embolism materials (5) of this utility model as embolism materials (2).Fig. 1 to Fig. 4.
Select for use morphine as analgesic (1), select for use gelfoam as embolism materials (2), select for use cardiografin as developing agent, morphine, cardiografin, gelfoam are mixed and made into microsphere, promptly obtained the novel vascular embolism materials (5) that can develop of this utility model.Fig. 1 to Fig. 4.
Select for use the dolantin injection as analgesic (1), select for use the porous polyethylene microsphere as embolism materials (2), dolantin is adsorbed in the micropore (3) of porous polyethylene microsphere, has promptly obtained the non-biodegradation type novel vascular embolism materials (5) that is adsorbed with analgesic (1) of this utility model.Fig. 5 to Fig. 8.
Analgesic (1) is coated on the non-biodegradation type solid vascular suppository material (2), has promptly obtained the non-biodegradation type novel vascular embolism materials (5) that is coated with analgesic (1) of this utility model.Fig. 9 to Figure 11.
Analgesic (1) is coated on the non-biodegradation type solid vascular suppository material (2), with porous silicon rubber as release membranes, also can adopt other release membranes, promptly obtain the non-biodegradation type novel vascular embolism materials (5) that has release membranes of this utility model.Figure 12 to Figure 14.
With recovery temperature is 33 ℃, and diameter is the Ultimum Ti filament winding system one-level helical spring of 0.15mm, then the one-level helical spring is regarded as a thick tinsel, and coiling deuterostrophies spring is through the typing heat treatment.To pull into the one-level helical spring through the deuterostrophies spring behind the typing heat treatment, coat with analgesic and morphine then, promptly obtain the helical spring type novel vascular embolism materials (5) of this utility model.Figure 15 to Figure 17.
With recovery temperature is 33 ℃, and diameter is the Ultimum Ti filament winding system one-level helical spring of 0.15mm, then the one-level helical spring is regarded as a thick tinsel, and coiling deuterostrophies spring is through the typing heat treatment.To pull into the one-level helical spring through the deuterostrophies spring behind the typing heat treatment, coat with analgesic and morphine then, the terylene fiber is wrapped on the one-level helical spring, has promptly obtained the helical spring type novel vascular embolism materials (5) of the band terylene fiber hair of this utility model.Figure 18 to Figure 20.
During clinical use,, select the novel vascular embolism materials (5) of suitable this utility model according to the vessel size that will stop up and diseased region.In intervene operation, the novel vascular embolism materials (5) of this utility model is injected the blood vessel (7) that will stop up by conduit (6).Because the existence of suppository causes thrombosis and finally blocks blood vessel, reaches the purpose of vascular embolization treatment disease; Along with slowly disengaging of analgesic, can solve the target pain that causes because of ischemia effectively, alleviate the patient suffering, Figure 21.
Claims (6)
1, novel vascular embolism materials, comprise analgesic (1), embolism materials (2), it is characterized in that analgesic (1) be entrained in the embolism materials (2) or analgesic (1) attached on the embolism materials (2), form nutty structure or block structure or linear structure or spring-like structures.
2, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can mix with anticarcinogen or other medicines, be entrained in the embolism materials (2) or attached on the embolism materials (2), form nutty structure or block structure or existing list structure or spring-like structures.
3,, it is characterized in that the embolism materials (2) of novel vascular embolism materials can be the Biodegradable vascular suppository material, as gelfoam, sodium alginate, polyglycolic acid, polylactic acid, Ju diox etc. according to the described novel vascular embolism materials of claim 1; Also can be non-Biodegradable vascular suppository material, as metal spring steel ring class: steel rim of spring, Ultimum Ti steel rim of spring, stainless steel spring steel ring, the platinum steel rim of spring of band terylene fiber hair; Macromolecule material particle class: polyvinyl alcohol (Polyvinyl Alcohol, PVA) microgranule, politef microgranule, polyethylene microgranule, polyamine fat microgranule, nylon microgranule etc., perhaps porous material particulate species: POROUS TITANIUM metal particle, porous polyethylene microgranule, porous Teflon microgranule, porous polyethylene alcohol microgranule etc.
4, according to the described novel vascular embolism materials of claim 1, the embolism materials (2) that it is characterized in that the novel vascular embolism materials can be to develop under the X-ray, also can be that X-ray is nonvisualized.
5, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can be that solid-state drug is entrained in the embolism materials (2) or is coated in the embolism materials (2), also can be liquid drug be adsorbed on porous embolism materials (2) micropore (3) in.
6, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can be entrained in the embolism materials (2) or attached on the embolism materials (2), discharge gradually by release membranes (4).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02248907 CN2576179Y (en) | 2002-10-25 | 2002-10-25 | Novel blood-vessel embolism material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02248907 CN2576179Y (en) | 2002-10-25 | 2002-10-25 | Novel blood-vessel embolism material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2576179Y true CN2576179Y (en) | 2003-10-01 |
Family
ID=33719448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02248907 Expired - Fee Related CN2576179Y (en) | 2002-10-25 | 2002-10-25 | Novel blood-vessel embolism material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2576179Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025270A (en) * | 2010-06-07 | 2013-04-03 | 库克医药技术有限责任公司 | Reperfusion catheter system |
| CN104739479A (en) * | 2013-12-31 | 2015-07-01 | 微创神通医疗科技（上海）有限公司 | Spring coil and production method thereof |
-
2002
- 2002-10-25 CN CN 02248907 patent/CN2576179Y/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025270A (en) * | 2010-06-07 | 2013-04-03 | 库克医药技术有限责任公司 | Reperfusion catheter system |
| US9192746B2 (en) | 2010-06-07 | 2015-11-24 | Cook Medical Technologies Llc | Reperfusion catheter system |
| CN103025270B (en) * | 2010-06-07 | 2016-08-03 | 库克医药技术有限责任公司 | reperfusion catheter system |
| CN104739479A (en) * | 2013-12-31 | 2015-07-01 | 微创神通医疗科技（上海）有限公司 | Spring coil and production method thereof |
| WO2015101307A1 (en) * | 2013-12-31 | 2015-07-09 | 微创神通医疗科技（上海）有限公司 | Spring coil and preparation method thereof |
| CN104739479B (en) * | 2013-12-31 | 2017-11-03 | 微创神通医疗科技（上海）有限公司 | A kind of turn and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1224381C (en) | Fast-dispersing dosage forms containing fish gelatin | |
| US9549920B2 (en) | Methods and compositions for treating post-operative pain comprising a local anesthetic | |
| Robert et al. | Biocompatibility and resorbability of a polylactic acid membrane for periodontal guided tissue regeneration | |
| US8980317B2 (en) | Methods and compositions for treating infections comprising a local anesthetic | |
| EP2531220B1 (en) | Active scaffolds for on-demand drug and cell delivery | |
| JP2010047617A (en) | Composition for delivering tetracycline derivative | |
| TW200800298A (en) | Compressed microparticles for dry injection | |
| CN1413743A (en) | Vascular suppository material | |
| JP2011518180A (en) | Methods and compositions for treating post-operative pain comprising clonidine | |
| WO2012171478A1 (en) | Liquid embolic materials based on collagens and preparation method thereof | |
| AU6517900A (en) | Controlled release implantable devices | |
| Sampath et al. | Preparation and characterization of biodegradable poly (L-lactic acid) gentamicin delivery systems | |
| CA2548106A1 (en) | Therapeutic microparticles | |
| CN2576179Y (en) | Novel blood-vessel embolism material | |
| JP2000516839A (en) | Subcutaneous or intradermal implants | |
| JP2010502732A (en) | Method for treating tendonitis in a subject using an anti-cytokine agent | |
| CA2510320C (en) | Coated particles for sustained-release pharmaceutical administration | |
| JPH11206871A (en) | In vivo degradable and absorptive bone fixing material and its manufacture | |
| CN1698902A (en) | Reversal temperature sensitive injection type implantable drug supporter material | |
| AU2003299982B2 (en) | Coated particles for sustained-release pharmaceutical administration | |
| JP3023471B2 (en) | Internal fixation material for osteosynthesis | |
| CN1159069C (en) | Process for preparing medical 3D chitosan material | |
| JP3148932B2 (en) | Biodegradable and absorbable plate for internal fixation of fracture | |
| KR100835898B1 (en) | Poly vinyl alcohol hydrogel particle by using acid hydrolysis and method the same | |
| CN1176719C (en) | Application for protease in preparing anastaltic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGDONG DICK MEDICAL DEVICES CO., LTD. Free format text: FORMER OWNER: ZHOU XING Effective date: 20050225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20050225 Address after: 510663 Guangzhou international business incubator A, Science City, Guangzhou economic and Technological Development Zone, Guangzhou, Guangdong province A601 Patentee after: Guangzhou Dike Medical Equipment Co., Ltd. Address before: 510060 room 12, building 19, 601 martyrs South Road, Guangdong, Guangzhou Patentee before: Zhou Xing |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031001 Termination date: 20101025 |